Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa

Journal of Infectious Diseases

Volumn 214, Issue 6, 2016, Pages 873-883

  Boender, T Sonia ^a   Hamers, Raph L ^a,b   Ondoa, Pascale ^a   Wellington, Maureen ^b   Chimbetete, Cleophas ^b   Siwale, Margaret ^c   Labib Maksimos, Eman E F ^d   Balinda, Sheila N ^e   Kityo, Cissy M ^e   Adeyemo, Titilope A ^f   Akanmu, Alani Sulaimon ^f   Mandaliya, Kishor ^g   Botes, Mariette E ^h   Stevens, Wendy ⁱ   Rinke De Wit, Tobias F ^a   Sigaloff, Kim C E ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Newlands Clinic   (Zimbabwe)

^c Lusaka Trust Hospital   (Zambia)

^d Coptic Hospital ^*  (Zambia)

^e JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^f UNIVERSITY OF LAGOS   (Nigeria)

^g Department of Obstetrics and Gynaecology   (Kenya)

^h Muelmed Hospital   (South Africa)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

drug resistance; HIV 1; protease inhibitor; second line antiretroviral therapy; sub Saharan Africa

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; AFRICA SOUTH OF THE SAHARA; AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SECONDARY HEALTH CARE; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; ADOLESCENT; ANTIVIRAL RESISTANCE; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; MUTATION; PREVALENCE; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PREVALENCE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84984993524     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw219     Document Type: Conference Paper

References (45)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). MDG 6: 15 years, 15 lessons of hope from the AIDS response, 2015. http://www.unaids.org/en/resources/documents/2015/MDG6-15years-15lessonsfromtheAIDSresponse. Accessed April 2015.
2. World Health Organization. Antiretroviral medicines in low- and middle-income countries: forecasts of global and regional demand for 2012-2015, 2013. http://apps.who.int/iris/bitstream/10665/83148/1/9789241505468-eng.pdf. Accessed June 2013.
3. Estill J, Ford N, Salazar-Vizcaya L, et al. The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study. Lancet HIV 2016; 3:e132-9.
4. Haas AD, Keiser O, Balestre E, et al. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. Lancet HIV 2015; 271-8.
5. CHAI (The Clinton Health Access Initiative). ARV market report-the state of the antiretroviral drug market in low- and middle-income countries, 2013.
6. Médecins Sans Frontières. Untangling the web of antiretroviral price reductions: 17th edition-July 2014. http://www.msfaccess.org/content/untangling-webantiretroviral- price-reductions-17th-edition-july-2014.
7. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach -2010 revision, 2010. http://www.who.int/hiv/pub/arv/adult2010/en/.
8. WorldHealth Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection-recommendations for a public health approach, 2013. http://www.who.int/hiv/pub/guidelines/arv2013/download/en/.
9. World Health Organization. Access to antiretroviral drugs in low- and middleincome countries: technical report July 2014. http://www.who.int/hiv/pub/amds/ access-arv-2014/en/.
10. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 2012; 26:929-38.
11. De Beaudrap P, Thiam M, Diouf A, et al. Risk of virological failure and drug resistance during first and second-line antiretroviral therapy in a 10-year cohort in Senegal: results from the ANRS 1215 cohort. J Acquir Immune Defic Syndr 2013; 62:381-7.
12. Boyd MA, Kumarasamy N, Moore CL, et al. SECOND-LINE Study Group. Ritonavir- boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECONDLINE): a randomised, open-label, non-inferiority study. Lancet 2013; 381:2091-9.
13. Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371:234-47.
14. Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010; 11:510-8.
15. Wallis CL, Mellors JW, Venter WDF, Sanne I, Stevens W. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Res Treat 2011; 2011:1-5.
16. Johnston V, Cohen K, Wiesner L, et al. Viral suppression following switch to second-line antiretroviral therapy: Associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis 2014; 209:711-20.
17. Boyd MA, Moore CL, Molina J, et al. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Lancet HIV 2015; 2:e42-51.
18. Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr JAIDS 2012; 61:158-63.
19. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med 2012; 18:1378-85.
20. Garone DB, Conradie K, Patten G, et al. High rate of virological re-suppression among patients failing second-line antiretroviral therapy following enhanced adherence support: a model of care in Khayelitsha, South Africa. South African Med J 2013; 14:166-9.
21. Magambo B, Nazziwa J, Bbosa N, Gupta RK, Kaleebu P, Parry CM. The arrival of untreatable multidrug-resistant HIV-1 in sub-Saharan Africa. AIDS 2014; 28:1373-4.
22. Rawizza HE, Chaplin B, Meloni ST, et al. Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. PLoS One 2013; 8:1-8.
23. Saravanan S, Vidya M, Balakrishnan P, et al. Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India. Clin Infect Dis 2012; 54:995-1000.
24. Hamers RL, Oyomopito R, Kityo C, et al. Cohort profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol 2012; 41:43-54.
25. Sigaloff KCE, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
26. Sigaloff KCE, Hamers RL, Wallis CL, et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis 2012; 205:1739-44.
27. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006 revision). http://www.who.int/hiv/pub/arv/adult/en/. Accessed 10 May 2013.
28. Wallis CL, Papathanasopoulos MA, Lakhi S, et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods 2010; 163:505-8.
29. Wensing AM, Calvez V, Günthard HF, et al. 2015 Update of the drug resistance mutations in HIV-1. Top Antivir Med 2015; 23:132-41.
30. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608-18.
31. Pineda-Peña A-CC, Faria NR, Imbrechts S, et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol 2013; 19:337-48.
32. World Health Organization. Policy brief: consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: what's new, 2015. http://www.who.int/hiv/pub/arv/policy-brief-arv-2015/en/.
33. Pujades-Rodríguez M, Balkan S, Arnould L, Brinkhof MAW, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource- limited countries. JAMA 2010; 304:303-12.
34. Boettiger DC, Nguyen VK, Durier N, et al. Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database. J Acquir Immune Defic Syndr 2015; 68:186-95.
35. Van Zyl GU, Liu TF, Claassen M, et al. Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first- and second-line antiretroviral treatment regimens. PLoS One 2013; 8:4-11.
36. Kumarasamy N, Aga E, Ribaudo HJ, et al. Lopinavir/ritonavir monotherapy as second-line antiretroviral treatment in resource-limited settings: week 104 analysis of AIDS clinical trials group (ACTG) A5230. Clin Infect Dis 2015; 60:1552-8.
37. Grover D, Copas A, Green H, et al. What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother 2008; 61:705-13.
38. World Health Organization. Global update on HIV treatment 2013: results, impact and opportunities, 2013. http://www.who.int/hiv/pub/progressreports/update2013/en/. Accessed 16 June 2016.
39. CHAI UNAIDS and UNITAIDS. Three new agreements announced with the potential to expand access to innovative HIV treatment in low- and middle-income countries, 2015. http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2015/november/20151130-PR-CHAI-UNITAID. Accessed 8 January 2016.
40. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.
41. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998; 72:3300-6.
42. Sigaloff KCE, Hamers RL, Menke J, et al. Early warning indicators for populationbased monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis 2012; 54(suppl 4):S294-9.
43. Rabi SA, Laird GM, Durand CM, et al. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest 2013; 123:3848-60.
44. Fun A, Wensing AM, Verheyen J, Nijhuis M. Human immunodeficiency virus Gag and protease: partners in resistance. Retrovirology 2012; 9:1-14.
45. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-10.